Protalix BioTherapeutics (PLX) Work In Process (2012 - 2026)

Protalix BioTherapeutics has reported Work In Process for 9 years, with the latest figure at $8.3 million in Q2 2026.

• On a quarterly basis, Work In Process rose 1.35% year-over-year to $8.3 million in Q2 2026; TTM through Jun 2026 was $8.3 million, a 1.35% increase from a year earlier, with the FY2025 full-year figure at $9.4 million, down 16.63% from the prior year.
• Work In Process was $8.3 million for Q2 2026 at Protalix BioTherapeutics, down from $9.1 million in the prior quarter.
• The five-year high for Work In Process was $12.3 million in Q3 2024, with the low at $1.5 million in Q1 2023.
• Average Work In Process over 5 years is $7.0 million, with a median of $8.2 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Work In Process surged 498.11% in 2024, then plunged 56.29% in 2025.
• Over 5 years, Work In Process stood at $2.7 million in 2022, then soared by 238.13% to $9.1 million in 2023, then increased by 24.19% to $11.2 million in 2024, then fell by 16.63% to $9.4 million in 2025, then fell by 11.96% to $8.3 million in 2026.
• The last three Work In Process figures came in at $8.3 million (Q2 2026), $9.1 million (Q1 2026), and $9.4 million (Q4 2025), per Business Quant data.